An increase in the prevalence of severe and genetic disorders, increase in the number aptamer-based therapeutic applications, and an increase in awareness of the advantages of aptamers over monoclonal antibodies will propel the growth of the aptamers market in forecast period.
Aptamers are being used to undertake diagnostic and therapeutic against several diseases. Their key benefits, which include lower cost, the ability to not kill nearby cells, higher binding attachment, extended shelf life, and specificity.
The global aptamers market is estimated to expand at a CAGR of 21% between 2023 to 2032.
The aptamers market size was estimated to be US$ 1.79 billion in 2021.
The global aptamers market was led by North America mainly because of higher R&D spending and technological developments in this region. Due to encouraging federal programs and an increase in research facilities, the United States is currently dominating the North American market.
Among some of the largest companies in the global aptamers market include Aptus Biotech S.L., Aptamer Group, Aptamer Sciences Inc., Base Pair Biotechnologies Inc., TriLink BioTechnologies LLC, IBA GmbH, Kaneka Eurogentec S.A. (Kaneka Corporation), NeoVentures Biotechnology Inc., Vivonics Inc., Aptagen LLC, NOXXON Pharma, SomaLogic Inc., and Aptamer Sciencesase (PR)
Copyright © 2023 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved